Skip to main content
. 2015 Jan;36(1):178–187. doi: 10.1016/j.neurobiolaging.2014.07.032

Fig. 4.

Fig. 4

(−)-Epicatechin causes a trend toward reduced β-CTF without affecting APP levels or α-secretase mediated APP metabolites. (A) (−)-Epicatechin does not cause a time or concentration dependent alteration in total APP levels or α-CTF levels as seen with 50 μM NMDA (a) 20 minutes, (b) 6 hours, and (c) 24 hours treatment. Western blot was performed with monoclonal CT20 (1:75,000) antibody. (B) No significant change in sAPPα or total APP695 protein levels following 0.1 μM (−)-epicatechin over time course from 0.5 to 24 hours. Western blot analysis was performed with monoclonal antibody supernatant 5G11 for sAPPα (1:9), antibody 22C11 for APP (1:5000), and T8328 β tubulin (1:10,000), representative blots are shown. (C) (−)-Epicatechin (0.1 μM) caused a trend toward a time-dependent reduction in β-CTF levels in the absence of increased α-CTF levels measured at (a) 20 minutes, (b) 6 hours, and (c) 24 hours treatment, n = 3. Abbreviation: APP, amyloid precursor protein; CTF, C-terminal fragments.